Roy Tatenda Bisenti

Prof. Roy Tatenda Bisenti


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RBRoy Tatenda Bisenti
Roy Tatenda Bisenti
TSTinashe Sibamba
Tinashe Sibamba
GMGlee Chipo Murirawanhu
Glee Chipo Murirawanhu
MZMark Fungai Zaranyika
Mark Fungai Zaranyika
AWAlbert Wakandigara
Albert Wakandigara
PMPaul Mushonga
Paul Mushonga
Hypertension is a leading global health burden, with dihydropyridine calcium channel blockers (DHP CCBs) serving as a primary therapeutic class. However, the molecular and pharmacokinetic determinants underlying their variable clinical efficacy remain incom-pletely understood. This in silico study investigated the structural and ADME basis for the differential activity of five DHP drugs (amlodipine, nifedipine, isradipine, nicardipine, nisoldipine) targeting the L-type calcium channel CaV1.2. Molecular docking (Glide-XP), MM-GBSA binding free energy calculations using the human CaV1.2 structure (PDB: 8WE8), and ADME predictions (QikProp, CYP3A4 site of metabolism) were integrated. Results identified a conserved hydrogen bond with residue SER1132 (bond length range: 1.931–2.094 Å) as a key binding anchor. The Coulombic interaction energy (range: -74174.2 to -74202.3 kcal/mol) showed a strong inverse correlation with experimental IC₅₀ (0.013–0.194 µM), establishing it as a primary affinity determinant. Pharmacokinetically, predicted human serum albumin binding (QPlogKhsa: 0.237–0.770) directly correlated with IC₅₀, and metabolic vulnerability to CYP3A4 varied notably among the drugs. These findings demonstrate that the differential potency of DHP CCBs arises from a combination of target engagement strength, governed by electrostatic interactions and a conserved SER1132 anchor, and key ADME properties, providing a computational framework for ra-tional antihypertensive drug design.

3 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TMTafara Masuka
Tafara Masuka
RBRoy Tatenda Bisenti
Roy Tatenda Bisenti
CCCraig Chirenje
Craig Chirenje
ANAdoren Ngarivhume
Adoren Ngarivhume
AWAlbert Wakandigara
Albert Wakandigara
MZMark Fungai Zaranyika
Mark Fungai Zaranyika
Background/Objectives: Sulphonylureas (SUs) are a cost-effective first-line treatment for Type 2 Diabetes Mellitus (T2DM), yet the precise bioorganic mechanisms governing their activity and the variation in their hypoglycemic effects are not fully elucidated. This study aimed to computationally determine the structural basis for the activity of SUs on the sulphonylurea receptor 1 (SUR1) and to identify the factors responsible for their differing potencies and durations of action. Methods: A computational chemistry approach was employed to analyze first- and second-generation sulphonylureas. The methods included molecular docking to simulate drug-receptor binding, Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations to estimate binding free energies, and the prediction of cytochrome P450 (CYP450) sites of metabolism to assess metabolic stability. Results: Molecular docking identified critical interactions between all SUs and the amino acid residues ARG 1300, ARG 1246, and ARG 4 on SUR1. The total hydrogen bond energy was found to be inversely proportional to the drugs’ potencies. Furthermore, the intrinsic reactivity of the predicted CYP450 metabolism sites was inversely proportional to the drugs’ observed half-lives. Conclusions: The activity of sulphonylureas on SUR1 is primarily driven by interactions with key arginine residues (ARG 1300, ARG 1246, and ARG 4). The variation in drug potency is explained by differences in total hydrogen bond energy, while the diversity in their hypoglycemic durations is attributed to their differing metabolic stability as determined by CYP450 intrinsic reactivity.